open access

Vol 12, No 4 (2019)
REVIEWS
Published online: 2020-01-10
Get Citation

Molecular biology methods for blood cell antigens genotyping in reference laboratories

Katarzyna Guz, Agnieszka Orzińska, Bogumiła Michalewska, Monika Pelc-Kłopotowska, Ewa Brojer, Magdalena Łętowska
Journal of Transfusion Medicine 2019;12(4):191-198.

open access

Vol 12, No 4 (2019)
REVIEWS
Published online: 2020-01-10

Abstract

The aim of the study is to present current applications of molecular biology in immunohematology and the status of their implementation in the Polish Blood Transfusion Service. Molecular biology methods are used for: analysis of molecular background of blood cell antigens in individuals with discrepant results of serological tests, identification of RhD antigen with weak expression undetectable by serological methods, identification of weak D type in recipients not susceptible to alloimmunization, non-invasive study of fetal genes in women with serological incompatibilities and in RhD negative women for the qualification of antenatal administration of anti-D and for antigen determination of "antigen-negative” donors. All tests are available and used in Poland.

Abstract

The aim of the study is to present current applications of molecular biology in immunohematology and the status of their implementation in the Polish Blood Transfusion Service. Molecular biology methods are used for: analysis of molecular background of blood cell antigens in individuals with discrepant results of serological tests, identification of RhD antigen with weak expression undetectable by serological methods, identification of weak D type in recipients not susceptible to alloimmunization, non-invasive study of fetal genes in women with serological incompatibilities and in RhD negative women for the qualification of antenatal administration of anti-D and for antigen determination of "antigen-negative” donors. All tests are available and used in Poland.
Get Citation

Keywords

genetic testing

About this article
Title

Molecular biology methods for blood cell antigens genotyping in reference laboratories

Journal

Journal of Transfusion Medicine

Issue

Vol 12, No 4 (2019)

Pages

191-198

Published online

2020-01-10

Bibliographic record

Journal of Transfusion Medicine 2019;12(4):191-198.

Keywords

genetic testing

Authors

Katarzyna Guz
Agnieszka Orzińska
Bogumiła Michalewska
Monika Pelc-Kłopotowska
Ewa Brojer
Magdalena Łętowska

References (59)
  1. Yamamoto F, Marken J, Tsuji T, et al. Cloning and characterization of DNA complementary to human UDP-GalNAc: Fuc alpha 1----2Gal alpha 1----3GalNAc transferase (histo-blood group A transferase) mRNA. J Biol Chem. 1990; 265(2): 1146–1151.
  2. Daniels G. Human Blood Groups, 3rd Edition. Wiley-Blackwell 2013.
  3. Reid ME, Lomas-Francis C, Olsson M. The blood group antigen. 3rd Edition. Elsevier Ltd London, UK 2012.
  4. Newman PJ, Derbes RS, Aster RH. The human platelet alloantigens, PlA1 and PlA2, are associated with a leucine33/proline33 amino acid polymorphism in membrane glycoprotein IIIa, and are distinguishable by DNA typing. J Clin Invest. 1989; 83(5): 1778–1781.
  5. Huizinga TW, Kleijer M, Tetteroo PA, et al. Biallelic neutrophil Na-antigen system is associated with a polymorphism on the phospho-inositol-linked Fc gamma receptor III (CD16). Blood. 1990; 75(1): 213–217.
  6. Brojer E, Uhrynowska M, Drzewek K, et al. Serologiczna i genetyczna analiza częstości antygenów NA ludzkich granulocytów. Acta Haematol Pol. 1997; 28: 155–162.
  7. Drzewek K, Brojer E, Zupańska B. The frequency of human platelet antigen (HPA) genotypes in the Polish population. Transfus Med. 1998; 8(4): 339–342.
  8. Guz K, Brojer E, Zupańska B. Implications of NA1/NA2 and SH genotyping results in the Polish population with regard to the new nomenclature of granulocyte alloantigens. Transfusion. 2000; 40(4): 490–1; author reply 492.
  9. Guz K, Orzińska A, Brojer E. Przegląd metod genotypowania antygenów krwinek czerwonych. J Transfus Med. 2013; 6: 90–95.
  10. Orzińska A, Guz K, Brojer E. Nowe osiągnięcia w badaniach nad podstawami molekularnymi grup krwi. J Transfus Med. 2013; 6: 101–104.
  11. Westhoff CM. Molecular DNA-based testing for blood group antigens: recipient-donor focus. ISBT Science Series. 2013; 8(1): 1–5.
  12. Peyrard T. Use of genomics for decision-making in transfusion medicine: laboratory practice. ISBT Science Series. 2013; 8(1): 11–15.
  13. Svensson A, Delaney M. Considerations of red blood cell molecular testing in transfusion medicine. Expert Rev Mol Diagn. 2015; 15: 1455–1464.
  14. Reid ME, Denomme GA. DNA-based methods in the immunohematology reference laboratory. Transfus Apher Sci. 2011; 44(1): 65–72.
  15. Haer-Wigman L, Ji Y, Lodén M, et al. Comprehensive genotyping for 18 blood group systems using a multiplex ligation-dependent probe amplification assay shows a high degree of accuracy. Transfusion. 2013; 53(11 Suppl 2): 2899–2909.
  16. Guz K, Orzińska A, Brojer E. Rozwój technologii opartych na metodach biologii molekularnej do oznaczania grup krwi. Journal of Transfusion Medicine. 2019; 12(2): 56–64.
  17. Orzinska A, Guz K, Brojer E.

    Potential of next-generation sequencing to match blood group antigens for transfusion

    . International Journal of Clinical Transfusion Medicine. 2019; Volume 7: 11–22.
  18. Michalewska B, Żupańska B, Pelc-Kłopotowska M, et al. Alloimmunizacja u chorych na niedokrwistość auto-immunohemolityczną oraz genotypowanie krwinek czerwonych w celu udoskonalenia doboru krwi do przetoczeń. J Transfus Med. 2009; 2: 14–19.
  19. Olsson ML, Michalewska B, Hellberg A, et al. A clue to the basis of allelic enhancement: occurrence of the Ax subgroup in the offspring of blood group O parents. Transfus Med. 2005; 15(5): 435–442.
  20. Polin H, Pelc-Klopotowska M, Danzer M, et al. Compound heterozygosity of two novel RHAG alleles leads to a considerable disruption of the Rh complex. Transfusion. 2016; 56(4): 950–955.
  21. Mota M, Fonseca NL, Rodrigues A, et al. Anti-D alloimmunization by weak D type 1 red blood cells with a very low antigen density. Vox Sang. 2005; 88: 130–135.
  22. St-Louis M, Lebrun A, Goldman M, et al. Alloimmunization of patients by blood units harboring distinct DEL variants. Immunohematology. 2013; 29(4): 136–140.
  23. Orzińska A, Guz K, Polin H, et al. RHD variants in Polish blood donors routinely typed as D-. Transfusion. 2013; 53(11 Suppl 2): 2945–2953.
  24. Pelc-Kłopotowska M, Orzińska A, Michalewska B, et al. Badanie obecności fragmentów genu RHD u dawców RhD ujemnych z zastosowaniem minipulowania i technologii real-time PCR. J Transfus Med. 2008; 1: 40–45.
  25. Flegel WA, Wagner FF, Müller TH, et al. Rh phenotype prediction by DNA typing and its application to practice. Transfus Med. 1998; 8(4): 281–302.
  26. Crottet SL, Henny C, Meyer S, et al. Implementation of a mandatory donor RHD screening in Switzerland. Transfus Apher Sci. 2014; 50(2): 169–174.
  27. Sandler SG, Chen LN, Flegel WA. Serological weak D phenotypes: a review and guidance for interpreting the RhD blood type using the RHD genotype. Br J Haematol. 2017; 179(1): 10–19.
  28. Pham BN, Roussel M, Gien D, et al. Molecular analysis of patients with weak D and serologic analysis of those with anti-D (excluding type 1 and type 2). Immunohematology. 2013; 29(2): 55–62.
  29. Pelc-Kłopotowska M, Guz K, Orzińska A, et al. Evaluation of reactivity of various monoclonal anti-D reagents with red blood cells of individuals with inconclusive RHD variants. XXVIII PTHiT, Łodź 12-14.09. 2019, Zeszyt Streszcze. : 58–59.
  30. Pelc-Kłopotowska M, Guz K, Wróbel J, et al. Charakterystyka molekularna i serologiczna słabych odmian antygenu D u dawców RCKiK w Białymstoku. Acta Haematologica Polonica. 2015; 46: 123.
  31. Orzińska A, Guz K, Brojer E, et al. Badanie genu RHD płodu w osoczu zimmunizowanej matki Rh ujemnej pozwoliło na uniknięcie metod inwazyjnych i urodzenie zdrowego dziecka. Gin Pol. 2004; 75. ; 12: 963–965.
  32. Guz K, Brojer E, Żupańska B, et al. Nieinwazyjna diagnostyka RHD płodu u RhD ujemnych kobiet ciężarnych – wyniki wstępne. Gin Pol. 2004; 75: 21–25.
  33. Brojer E, Zupanska B, Guz K, et al. Noninvasive determination of fetal RHD status by examination of cell-free DNA in maternal plasma. Transfusion. 2005; 45(9): 1473–1480.
  34. Orzińska A, Guz K, Brojer E, et al. Preliminary results of fetal Rhc examination in plasma of pregnant women with anti-c. Prenat Diagn. 2008; 28(4): 335–337.
  35. Orzińska A, Guz K, Gala K, et al. The influence of methods of maternal collection and storage and DNA isolation on detection of fetal genes in maternal plasma in noninvasive prenatal diagnostics. Diagn Lab. 2007; 43: 69–77.
  36. Orzińska A, Guz K, Dębska M, et al. 14 Years of Polish Experience in Non-Invasive Prenatal Blood Group Diagnosis. Transfus Med Hemother. 2015; 42(6): 361–364.
  37. Clausen FB, Steffensen R, Christiansen M, et al. Routine noninvasive prenatal screening for fetal RHD in plasma of RhD-negative pregnant women-2 years of screening experience from Denmark. Prenat Diagn. 2014; 34(10): 1000–1005.
  38. Thurik FF, Ait Soussan A, Bossers B, et al. Analysis of false-positive results of fetal RHD typing in a national screening program reveals vanishing twins as potential cause for discrepancy. Prenat Diagn. 2015; 35(8): 754–760.
  39. Szczepura A, Osipenko L, Freeman K. A new fetal RHD genotyping test: costs and benefits of mass testing to target antenatal anti-D prophylaxis in England and Wales. BMC Pregnancy Childbirth. 2011; 11: 5.
  40. Tiblad E, Taune Wikman A, Ajne G, et al. Targeted routine antenatal anti-D prophylaxis in the prevention of RhD immunisation-outcome of a new antenatal screening and prevention program. PLoS One. 2013; 8(8): e70984.
  41. Orzińska A, Guz K, Purchla-Szepioła S, et al. 2-year experience in non-invasive prenatal diagnostics of fetal rhd for targeted anti-d immunoprophylaxis in Poland . Vox Sanguinis. 2018; 113(Suppl. 1): 276.
  42. Orzińska A, Guz K, et al. Purchla-Szepioła 3-lata nieinwazyjnej diagnostyki RHD płodu dla celowanej śródciążowej immunoprofilaktyki anty-D. XXVIII PTHiT, Łodź 12-14.09. 2019, Zeszyt Streszcze. : 95–96.
  43. Michalewska B. Częstość niezgodnych prób krzyżowych przy braku alloprzeciwcial wykrywanych w badaniach przeglądowych. Acta Haemat Pol. 2002; 33: 205–212.
  44. Michalewska B, Pelc-Kłopotowska M, Łopieńska H, et al. Ocena w teście erytrofagocytozy klinicznego znaczenia rzadko wykrywanych alloprzeciwciał czerwonokrwinkowych. Acta Haemat Pol. 2006; 37: 407–414.
  45. Łopieńska H, Michalik M, Ożóg A, et al. Alloprzeciwciała do antygenów występujących z wysoką częstością wykryte w Polsce w latach 2000–2012. Acta Haematologica Polonica. 2013; 44: 120.
  46. Pelc-Kłopotowska M, Guz K, Orzińska A, et al. Antibodies against high frequency antygen in Polish patients between 2000 and 2017. Vox Sang. 2018; 113(Supp. 1): 227.
  47. Orzińska A, Guz K, Michalewska B, et al. Molecular screening of the C antigen for typing donors compatible with patients with anti-MAR-like antibodies. Blood Transfus. 2016; 14(6): 573–576.
  48. Guz K, Orzińska A, Pelc-Kłopotowska M, et al. Identification of blood donors with rare red blood cell phenotypes using low-cost protocols. Vox Sang. 2018; 113(Suppl. 1): 263.
  49. Li RS, Qiao ZL, Ling B, et al. Establishment of reference panel for human platelet antigen genotyping. Vox Sang. 2014; 107(2): 166–170.
  50. Merzoni J, Fagundes IS, Lunardi LW, et al. Human platelet antigen genotyping of platelet donors in southern Brazil. Int J Immunogenet. 2015; 42(5): 329–335.
  51. Maślanka K, Guz K, Uhrynowska M, et al. Rejestr dawców z oznaczonymi swoistymi antygenami płytek krwi (HPA) i jego zastosowanie w transfuzjologii. Acta Haematol Pol. 2005; 36: 189–196.
  52. Guz K, Łopacz P, Gierszon A, et al. Ocena dostępności dawców koncentratów płytkowych o oznaczonych antygenach leukocytarnych i płytkowych dla pacjentów z przeciwciałami anty-HLA i/lub anty-HPA. J Transfus Med. 2019; 12(1): 1–12.
  53. Lucas GF, Bendukidize N. HPA-1a(-), 5b(-) platelets for use in neonatal alloimmune thrombocytopenia--from 'Cinderella' product to standard component. Transfus Med. 2014; 24(2): 127–129.
  54. Bertrand G, Kaplan C. How do we treat fetal and neonatal alloimmune thrombocytopenia? Transfusion. 2014; 54(7): 1698–1703.
  55. Uhrynowska ME, Dębska M, Guz K, et al. [PREVFNAIT prevention of foetal/neonatal alloimmune thrombocytopenia (FNAIT) in Polish foetuses and newborns--the PREVFNAIT program]. Ginekol Pol. 2015; 86(1): 62–66.
  56. Brojer E, Husebekk A, Dębska M, et al. Fetal/Neonatal Alloimmune Thrombocytopenia: Pathogenesis, Diagnostics and Prevention. Arch Immunol Ther Exp (Warsz). 2016; 64(4): 279–290.
  57. Weinstock C, Schnaidt M. Human Leucocyte Antigen Sensitisation and Its Impact on Transfusion Practice. Transfus Med Hemother. 2019; 46(5): 356–369.
  58. Storch EK, Hillyer CD, Shaz BH. Spotlight on pathogenesis of TRALI: HNA-3a (CTL2) antibodies. Blood. 2014; 124(12): 1868–1872.
  59. Bougie DW, Peterson JA, Kanack AJ, et al. Transfusion-related acute lung injury-associated HNA-3a antibodies recognize complex determinants on choline transporter-like protein 2. Transfusion. 2014; 54(12): 3208–3215.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Journal of Transfusion Medicine dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest Via Medica sp. z o.o. sp. komandytowa, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl